443 related articles for article (PubMed ID: 24809637)
1. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
[TBL] [Abstract][Full Text] [Related]
2. Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma.
Artzi M; Blumenthal DT; Bokstein F; Nadav G; Liberman G; Aizenstein O; Ben Bashat D
J Neurooncol; 2015 Jan; 121(2):349-57. PubMed ID: 25370705
[TBL] [Abstract][Full Text] [Related]
3. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
[TBL] [Abstract][Full Text] [Related]
4. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
5. Automatic multi-modal MR tissue classification for the assessment of response to bevacizumab in patients with glioblastoma.
Liberman G; Louzoun Y; Aizenstein O; Blumenthal DT; Bokstein F; Palmon M; Corn BW; Ben Bashat D
Eur J Radiol; 2013 Feb; 82(2):e87-94. PubMed ID: 23017192
[TBL] [Abstract][Full Text] [Related]
6. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
7. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
8. On differentiation between vasogenic edema and non-enhancing tumor in high-grade glioma patients using a support vector machine classifier based upon pre and post-surgery MRI images.
Sengupta A; Agarwal S; Gupta PK; Ahlawat S; Patir R; Gupta RK; Singh A
Eur J Radiol; 2018 Sep; 106():199-208. PubMed ID: 30150045
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.
Kickingereder P; Brugnara G; Hansen MB; Nowosielski M; Pflüger I; Schell M; Isensee F; Foltyn M; Neuberger U; Kessler T; Sahm F; Wick A; Heiland S; Weller M; Platten M; von Deimling A; Maier-Hein KH; Østergaard L; van den Bent MJ; Gorlia T; Wick W; Bendszus M
Radiology; 2020 Oct; 297(1):164-175. PubMed ID: 32720870
[TBL] [Abstract][Full Text] [Related]
10. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
[TBL] [Abstract][Full Text] [Related]
11. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
12. Decrease in the apparent diffusion coefficient in peritumoral edema for the assessment of recurrent glioblastoma treated by bevacizumab.
Takano S; Kimu H; Tsuda K; Osuka S; Nakai K; Yamamoto T; Ishikawa E; Akutsu H; Matsuda M; Matsumura A
Acta Neurochir Suppl; 2013; 118():185-9. PubMed ID: 23564129
[TBL] [Abstract][Full Text] [Related]
13. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
[TBL] [Abstract][Full Text] [Related]
14. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E
Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076
[TBL] [Abstract][Full Text] [Related]
15. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
17. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
18. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
19. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
[TBL] [Abstract][Full Text] [Related]
20. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.
Nowosielski M; Wiestler B; Goebel G; Hutterer M; Schlemmer HP; Stockhammer G; Wick W; Bendszus M; Radbruch A
Neurology; 2014 May; 82(19):1684-92. PubMed ID: 24727314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
